Randomized trial of steroid-free induction versus corticosteroid maintenance among orthotopic liver transplant recipients with hepatitis C virus: Impact on hepatic fibrosis progression at one year

被引:72
作者
Kato, Tomoaki
Gaynor, Jeffrey J.
Yoshida, Hideo
Montalvano, Marzia
Takahashi, Hidenori
Pyrsopoulos, Nikolaos
Nishida, Seigo
Moon, Jang
Selvaggi, Gennaro
Levi, David
Ruiz, Phillip
Schiff, Eugene
Tzakis, Andreas
机构
[1] Univ Miami, Sch Med, Dept Surg, Miami, FL 33152 USA
[2] Univ Miami, Sch Med, Dept Hepatol, Miami, FL 33152 USA
[3] Univ Miami, Sch Med, Dept Pathol, Miami, FL 33152 USA
关键词
daclizumab induction; steroid-free maintenance; mycophenolate mofetil; hepatitis C virus; orthotopic liver transplantation;
D O I
10.1097/01.tp.0000282914.20578.7b
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Due to the known high recurrence rate of hepatitis C virus (HCV) among orthotopic liver transplant (OLT) recipients who receive tacrolimus+corticosteroid maintenance, use of steroid-free induction was considered. Methods. OLT recipients with HCV were randomized to receive tacrolimus+daclizumab (steroid-free) vs. tacrolimus+corticosteroids during 1999-2001 and then tacrolimus+mycophenolate mofetil (MMF)+daclizumab (steroid-free) vs. tacrolimus+MMF+corticosteroids during 2002-2005. Patients in the steroid-free arm of both periods received no steroids except for treating biopsy-proven rejection. Primary objective was to compare mean fibrosis stage at the 1-year protocol biopsy, between the steroid-free and corticosteroid arms, stratifying by period. Results. No noticeable differences in mean fibrosis stage between the two treatment arms, either averaging across periods (P=0.99) or during either period (P > 0.35) were found. Occurrence of acute rejection during the first year was the only factor associated with a significantly increased fibrosis stage at 1 year (P=0.0003); stage ?2 was seen in 63% (17 of 27) vs. 19% (8 of 43) of those with vs. without rejection. In addition, MMF use.was associated with significantly fewer patients experiencing acute rejection during the first 6 and 12 months posttransplant (P=0.006 and 0.046). Regarding steroid-related side effects, posttransplant diabetes mellitus occurred in 10% vs. 45%, and wound infection in 6% vs. 31% of steroid-free vs. corticosteroid patients (P=0.003 and 0.01). Conclusions. OLT recipients with HCV tolerated the steroid-free protocol with fewer side effects; however, its use had no apparent impact on hepatic fibrosis progression. Occurrence of acute rejection was strongly associated with increased hepatic fibrosis at 1 year, and MNIF use appears to have significantly reduced the rejection rate.
引用
收藏
页码:829 / 835
页数:7
相关论文
共 24 条
[1]   MMF and calcineurin taper in recurrent hepatitis C after liver transplantation: Impact on histological course [J].
Bahra, M ;
Neumann, UP ;
Jacob, D ;
Puhl, G ;
Klupp, J ;
Langrehr, JM ;
Berg, T ;
Neuhaus, P .
AMERICAN JOURNAL OF TRANSPLANTATION, 2005, 5 (02) :406-411
[2]   Tapering off steroids three months after liver transplantation is not detrimental for hepatitis C virus disease recurrence [J].
Belli, LS ;
Alberti, AB ;
Vangeli, M ;
Airoldi, A ;
Pinzello, G .
LIVER TRANSPLANTATION, 2003, 9 (02) :201-202
[3]   A model to predict severe HCV-related disease following liver transplantation [J].
Berenguer, M ;
Crippin, J ;
Gish, R ;
Bass, N ;
Bostrom, A ;
Netto, G ;
Alonzo, J ;
Garcia-Kennedy, R ;
Rayón, JM ;
Wright, TL .
HEPATOLOGY, 2003, 38 (01) :34-41
[4]   Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients [J].
Berenguer, M ;
Prieto, M ;
San Juan, F ;
Rayón, JM ;
Martinez, F ;
Carrasco, D ;
Moya, A ;
Orbis, F ;
Mir, J ;
Berenguer, J .
HEPATOLOGY, 2002, 36 (01) :202-210
[5]   Slowly tapering off steroids protects the graft against hepatitis C recurrence after liver transplantation [J].
Brillanti, S ;
Vivarelli, M ;
De Ruvo, N ;
Aden, AA ;
Camaggi, V ;
D'Errico, A ;
Furlini, G ;
Bellusci, R ;
Roda, E ;
Cavallari, A .
LIVER TRANSPLANTATION, 2002, 8 (10) :884-888
[6]   Predictors of patient and graft survival following liver transplantation for hepatitis C [J].
Charlton, M ;
Seaberg, E ;
Wiesner, R ;
Everhart, J ;
Zetterman, R ;
Lake, J ;
Detre, K ;
Hoofnagle, J .
HEPATOLOGY, 1998, 28 (03) :823-830
[7]  
Demetris AJ, 1997, HEPATOLOGY, V25, P658
[8]   Impact of immunosuppressive therapy on recurrence of hepatitis C [J].
Everson, GT .
LIVER TRANSPLANTATION, 2002, 8 (10) :S19-S27
[9]   European collaborative study on factors influencing outcome after liver transplantation for hepatitis C [J].
Féray, C ;
Caccamo, L ;
Alexander, GJM ;
Ducot, B ;
Gugenheim, J ;
Casanovas, T ;
Loinaz, C ;
Gigou, M ;
Burra, P ;
Barkholt, L ;
Esteban, R ;
Bizollon, T ;
Lerut, J ;
Minello-Franza, A ;
Bernard, PH ;
Nachbaur, G ;
Botta-Fridlund, D ;
Bismuth, H ;
Schalm, SW ;
Samuel, D .
GASTROENTEROLOGY, 1999, 117 (03) :619-625
[10]   One-year protocol liver biopsy can stratify fibrosis progression in liver transplant recipients with recurrent hepatitis C infection [J].
Firpi, RJ ;
Abdelmalek, MF ;
Soldevila-Pico, C ;
Cabrera, R ;
Shuster, JJ ;
Theriaque, D ;
Reed, AI ;
Hemming, AW ;
Liu, C ;
Crawford, JM ;
Nelson, DR .
LIVER TRANSPLANTATION, 2004, 10 (10) :1240-1247